Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Allocation: Randomized Stratified
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants chronically infected with hepatitis C virus (HCV) genotype 1a or 1b
HCV RNA viral load ≥10,000 IU/mL
No prior treatment including but not limited to interferon, ribavirin, and direct-acting antivirals
No history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year
Body mass index of 18 to 35 kg/m\^2
Negative for HIV and hepatitis B virus
You may not be if
Evidence of decompensated liver disease
Evidence of medical condition other than HCV contributing to chronic liver disease
Clareo Health | Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
